- Home
- OKYO vs PMVP Comparison
OKYO vs PMVP Comparison
Compare OKYO & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OKYO | PMVP |
|---|---|---|
| Founded | 2007 | 2013 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.7M | 66.0M |
| IPO Year | 2022 | 2020 |
Fundamental Metrics
Financial Performance| Metric | OKYO | PMVP |
|---|---|---|
| Price | $2.76 | $1.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $6.00 | $5.00 |
| AVG Volume (30 Days) | 129.2K | ★ 215.5K |
| Earning Date | 07-18-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.90 | $0.81 |
| 52 Week High | $3.35 | $1.84 |
Technical Indicators
Market Signals| Indicator | OKYO | PMVP |
|---|---|---|
| Relative Strength Index (RSI) | 67.19 | 40.81 |
| Support Level | $1.90 | $1.20 |
| Resistance Level | $2.48 | $1.26 |
| Average True Range (ATR) | 0.20 | 0.05 |
| MACD | 0.07 | 0.00 |
| Stochastic Oscillator | 90.99 | 0.00 |
Price Performance
Historical ComparisonAbout OKYO OKYO Pharma Limited
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.